APRE (Aprea Therapeutics) Cash per Share : $4.20 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Aprea Therapeutics's Cash per Share for the quarter that ended in Dec. 2024 was $4.20.

Aprea Therapeutics Cash per Share Historical Data

The historical data trend for Aprea Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprea Therapeutics Cash per Share Chart

Aprea Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash per Share

Get a 7-Day Free Trial

84.06

48.56

10.84

5.78

4.20

Aprea Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash per Share	Get a 7-Day Free Trial															5.78	5.96	5.29	4.83	4.20

Aprea Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Aprea Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	22.85	/	5.44
	=	4.20

Aprea Therapeutics's Cash per Share for the quarter that ended in Dec. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	22.85	/	5.44
	=	4.20

Aprea Therapeutics (NAS:APRE) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Aprea Therapeutics Cash per Share Related Terms

Thank you for viewing the detailed overview of Aprea Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprea Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3805 Old Easton Road, Doylestown, PA, USA, 18902

Website

https://www.aprea.com

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Executives

Oren Gilad	officer: President, CEO	535 BOYLSTON STREET, BOSTON MA 02116
Marc Duey	director	27 STRATHMORE ROAD, NATICK MA 01760
Bernd R. Seizinger	director	535 BOYLSTON STREET, BOSTON MA 02116
John P. Hamill	officer: SrVP/CFO/Prin. Fin &Acctg. Off	4092 NEW HOPE ROAD, FURLONG PA 18925
Henneman John B Iii	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Jean-pierre Bizzari	director	235 LAUREL LN, HAVERFOLD PA 19041
Gabriela Gruia	director	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Grissinger	director	C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Rifat Pamukcu	director	535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade	director, officer: President & CEO	MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar	officer: SVP, Chief Medical Officer	535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel	officer: Chief Business Officer	535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen	officer: SVP, Chief Scientific Officer	535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green	10 percent owner	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129